PharmiWeb Today Story
Braveheart Bio has officially launched with a mission to transform cardiovascular medicine through advanced small-molecule therapies. The new biotech, led by CEO Travis Murdoch, is backed by leading investors including Forbion and OrbiMed, and debuts with a high-value licensing agreement with Jiangsu Hengrui Pharmaceuticals.
Under the deal, Braveheart Bio gains exclusive global rights, excluding China, Hong Kong, Macao and Taiwan, to develop, manufacture and commercialise the cardiac myosin inhibitor HRS-1893. The agreement includes an upfront payment of 65 million USD, split evenly between cash and shares, with additional potential milestones worth over 1 billion USD and royalties on future sales.
HRS-1893 is currently in Phase III trials in China for obstructive hypertrophic cardiomyopathy and has already shown strong early-phase data, suggesting best-in-class potential. With this asset, Braveheart Bio is positioning itself against major players in the field, including Bristol Myers Squibb’s Camzyos.
By combining global development rights with seasoned scientific leadership and strong investor backing, Braveheart Bio is establishing itself as a bold new contender in the cardiovascular therapeutics market.
Read More...
Articles
ArcaScience press Q&A with Romain Clément
11-Sep-2025
Bridging the Women's Health Gap
09-Sep-2025
AI in Recruitment
01-Sep-2025
Why good science is key to good technology
14-Aug-2025
Featured Events
-
Next Generation Cancer Vaccine Development Summit…
07-Sep-2021 - 09-Sep-2021 -
1st International Conference “WE! are the Clinical…
18-Sep-2021 - 18-Sep-2021 -
Reuters Events: Cell & Gene Therapy USA 2021
28-Sep-2021 - 29-Sep-2021 -
Pharmaceutical Manufacturing and Packaging Congres…
20-Jun-2022 - 21-Jun-2022 -
How to impact, influence & inspire
07-Feb-2023 - 21-Feb-2023 -
Finding the Value in Strategic Outsourcing Partner…
22-Feb-2023 - 22-Feb-2023
News
-
2026 European Radiology Information System Playboo…
07-Nov-2025 -
Notice of Data Privacy Incident
07-Nov-2025 -
Dr. Todd H. Lanman Presents First-Ever Public Resu…
07-Nov-2025 -
Onco-Innovations' Inka Health Publishes Framework…
07-Nov-2025 -
Reporting of Transactions Made by Persons Discharg…
07-Nov-2025 -
Releaf Dispensary Ltd Announces UK Cannabis Survey…
07-Nov-2025